Search clinical trials for: moderate or severe renal impairment compared to subjects with normal renal function

Total 480790 results

Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Merck KGaA, Darmstadt, Germany

Completed

Pharmacokinetics in Subjects With Renal Impairment

Renal Impairment

Germany
Syndax Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

United States
Jazz Pharmaceuticals

Withdrawn

A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.

Renal Insufficiency | Kidney Disease
Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Zydus Therapeutics Inc.

Recruiting

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function

Renal Impairment

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment | Tuberculosis

United States
Madrigal Pharmaceuticals, Inc.

Enrolling by invitation

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Bayer

Completed

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

United States
Sagimet Biosciences Inc.

Completed

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Cirrhosis | Hepatic Impairment | Non-alcoholic Steatohepatitis

United States, Hungary
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Healthy Subjects | Subjects With Renal Impairment

China
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Renal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215

United States, Bulgaria
Amgen

Completed

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Hyperlipidemia | Mixed Dyslipidemia

United States
Bristol-Myers Squibb

Completed

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Thrombosis

United States
Novartis Pharmaceuticals

Completed

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment

United States, Romania
Novartis Pharmaceuticals

Completed

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Mild Moderate | or Severe Renal Impairment

Germany
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
CTI BioPharma
SGS S.A.

Completed

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany, Romania
ViiV Healthcare
GlaxoSmithKline

Completed

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

HIV Infections

United States
Pharmaceutical Project Solutions, Inc.
Cognitive Research Corporation

Completed

PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

Healthy

United States
Allergan

Completed

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Renal Function

United States
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Novartis Pharmaceuticals

Completed

Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function

Pharmacokinetics | Healthy Volunteer | Renal Impaired

Russian Federation, Germany, Serbia
AstraZeneca

Completed

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Renal Impairment

United States
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
Cumberland Pharmaceuticals

Completed

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Kidney Diseases | Hyponatremia

United States
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Nycomed
NPS Pharma

Completed

Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Renal Impairment

Germany
VIVUS LLC

Completed

To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

Renal
Pfizer
Medivation, Inc.

Completed

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Alzheimer's Disease | Huntington's Disease

United States
Bayer

Not yet recruiting

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Chronic Kidney Disease | Hepatic Impairment
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 Diabetes

United States, United Kingdom, Argentina, Puerto Rico
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

Canada
Chipscreen Biosciences, Ltd.

Recruiting

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Renal Impairment

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Hepatic Insufficiency | Neoplasms

Spain, United States, Germany, Argentina, Colombia, Greece
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

Renal Impairment | Healthy Volunteers

United States
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Hanmi Pharmaceutical Company Limited

Completed

Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Renal Impairment

United States
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Bayer

Withdrawn

A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

Renal Impairment | Healthy Volunteers | Diabetic Neuropathic Pain

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Renal Impairment | Healthy Volunteers

United States
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Chiesi Farmaceutici S.p.A.

Completed

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

Chronic Obstructive Pulmonary Disease

Bulgaria
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada
Bayer

Completed

A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function

Renal Impairment | Congestive Heart Failure

Germany
Sunshine Lake Pharma Co., Ltd.

Completed

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Renal Impairment

China

3

Subscribe